Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10^th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia.

Read more at globenewswire.com